Karyopharm Therapeutics (KPTI) Projected to Post Quarterly Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) is projected to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.45) per share and revenue of $31.3990 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. On average, analysts expect Karyopharm Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Karyopharm Therapeutics Stock Up 5.3%

Shares of KPTI stock traded up $0.46 during mid-day trading on Monday, reaching $9.23. 133,167 shares of the stock traded hands, compared to its average volume of 852,517. The stock’s fifty day simple moving average is $8.03 and its two-hundred day simple moving average is $7.10. Karyopharm Therapeutics has a 1-year low of $3.65 and a 1-year high of $10.99. The company has a market cap of $208.13 million, a price-to-earnings ratio of -0.55 and a beta of 0.80.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on KPTI shares. Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, March 25th. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Cantor Fitzgerald assumed coverage on Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an “overweight” rating on the stock. Piper Sandler restated an “overweight” rating and set a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Finally, HC Wainwright cut their target price on Karyopharm Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.43.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $74,000. T. Rowe Price Investment Management Inc. lifted its holdings in Karyopharm Therapeutics by 112.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after purchasing an additional 790,417 shares during the last quarter. Ikarian Capital LLC grew its stake in Karyopharm Therapeutics by 1,897.9% in the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after buying an additional 517,297 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at $95,000. Finally, Quadrature Capital Ltd purchased a new stake in Karyopharm Therapeutics in the fourth quarter valued at approximately $439,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.